Direct-to-consumer pharmaceutical startup Hims & Hers Health said it is selling injectable GLP-1 weight loss drugs for a fraction of the cost of brand-name competitors such as Wegovy and Ozempic.

Hims & Hers Health stock beat on earnings but suffered a steep sales slowdown in Q4. Hims & Hers is trying to figure out how to grow without selling GLP-1 drugs. 10 stocks we like better than Hims & ...

Hims & Hers Health will begin selling generic GLP-1 drugs in Canada for 149 Canadian dollars ($108.41) a month.

SAN FRANCISCO — Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded ...